229 related articles for article (PubMed ID: 20624674)
1. The economic impact of depression: resistance or severity?
Fostick L; Silberman A; Beckman M; Spivak B; Amital D
Eur Neuropsychopharmacol; 2010 Oct; 20(10):671-5. PubMed ID: 20624674
[TBL] [Abstract][Full Text] [Related]
2. Serious life events among resistant and non-resistant MDD patients.
Amital D; Fostick L; Silberman A; Beckman M; Spivak B
J Affect Disord; 2008 Oct; 110(3):260-4. PubMed ID: 18262654
[TBL] [Abstract][Full Text] [Related]
3. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.
Ivanova JI; Birnbaum HG; Kidolezi Y; Subramanian G; Khan SA; Stensland MD
Curr Med Res Opin; 2010 Oct; 26(10):2475-84. PubMed ID: 20825269
[TBL] [Abstract][Full Text] [Related]
4. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
5. Cost burden of treatment resistance in patients with depression.
Gibson TB; Jing Y; Smith Carls G; Kim E; Bagalman JE; Burton WN; Tran QV; Pikalov A; Goetzel RZ
Am J Manag Care; 2010 May; 16(5):370-7. PubMed ID: 20469957
[TBL] [Abstract][Full Text] [Related]
6. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
Asche CV; Joish VN; Camacho F; Drake CL
Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
[TBL] [Abstract][Full Text] [Related]
7. A follow-up study on features of sensory gating P50 in treatment-resistant depression patients.
Wang Y; Fang YR; Chen XS; Chen J; Wu ZG; Yuan CM; Yi ZH; Hong W; Zhang C; Cao L
Chin Med J (Engl); 2009 Dec; 122(24):2956-60. PubMed ID: 20137481
[TBL] [Abstract][Full Text] [Related]
8. Descriptive analysis of the economic burden of treatment resistance in a major depressive episode.
Cai Q; Sheehan JJ; Wu B; Alphs L; Connolly N; Benson C
Curr Med Res Opin; 2020 Feb; 36(2):329-335. PubMed ID: 31540559
[No Abstract] [Full Text] [Related]
9. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
[TBL] [Abstract][Full Text] [Related]
10. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
11. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance.
Birnbaum HG; Kessler RC; Kelley D; Ben-Hamadi R; Joish VN; Greenberg PE
Depress Anxiety; 2010; 27(1):78-89. PubMed ID: 19569060
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
[TBL] [Abstract][Full Text] [Related]
13. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
Pilon D; Sheehan JJ; Szukis H; Morrison L; Zhdanava M; Lefebvre P; Joshi K
J Affect Disord; 2019 Aug; 255():50-59. PubMed ID: 31128505
[TBL] [Abstract][Full Text] [Related]
14. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment.
Revicki DA; Simon GE; Chan K; Katon W; Heiligenstein J
J Fam Pract; 1998 Dec; 47(6):446-52. PubMed ID: 9866670
[TBL] [Abstract][Full Text] [Related]
15. Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness.
Maes M; Mihaylova I; Kubera M; Uytterhoeven M; Vrydags N; Bosmans E
Neuro Endocrinol Lett; 2009; 30(4):462-9. PubMed ID: 20010493
[TBL] [Abstract][Full Text] [Related]
16. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
17. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
[TBL] [Abstract][Full Text] [Related]
19. Patient preferences for depression treatment programs and willingness to pay for treatment.
Morey E; Thacher JA; Craighead WE
J Ment Health Policy Econ; 2007 Jun; 10(2):73-85. PubMed ID: 17603148
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
